Ann: Final Results in Phase 1 Trial of CORE NK Platform, page-5

https://chimerictherapeutics.com/wp-content/uploads/2021/12/Chimeric-Therapeutics-Newsletter-December-2021.pdf

Following up on @stockrock's comment:
the NK cells used in this phase 1 trial are not even going to be used the same way or at all in the future trials I believe. They are enhancing it, using them in a combination study and also developing CaR-NK cells…

As mentioned in the newsletter above, CORE-NK is merely the platform to build CAR-NK products:


(same link as above)

@turbo already mentioned a few highlights of this platform:

1. Established an efficacy signal.
2. Shown absence of GvHD = universal therapy.
3. Demonstrated cell persistence up to 28 days.
4. Successful cell expansion = efficient manufacturing.
5. Provided the basis for further developments.

Unlike FDA-approved CAR-T cells that come with heavy side-effects such as Cytokine Release Syndrome and also some patients developed GvHD, such side effects have not been reported when using CAR-NK cells. This has been mentioned in the thePhase 1 Clinical Data Presentation (07/03/2022):



CORE-NK however seems to address specifically known CAR-NK challenges:


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140022/

See @turbo's points 3 & 4:

limited proliferative potential of NK cells (4.):


https://chimerictherapeutics.com/wp-content/uploads/2022/03/CORE-NK-Platform-Phase-1-Clinical-Data-Presentation-7-March-2022.pdf

limited persistence upon infusion (3.):


(same link as above)

I found a few very promising statements in the nature article published by Dr Wald et al who designed and developed the CORE-NK platform:








https://www.nature.com/articles/s41598-019-51287-6


Whilst this is based on a preclinical study, the data is very promising and I'm looking forward to clinical results of CHM 1301,
CHM 2301, CHM 3301.